SCHEMBL25691489

SCHEMBL25691489

COP(=O)(S)OC[C@H]1O[C@@H](n2cnc3c(=O)n4ccnc4[nH]c32)[C@H](O)[C@@H]1OP(=O)(S)OC[C@@H]1C[C@@H](F)[C@H](n2cnc3c(N)ncnc32)O1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ P2RY1 P47900 5/20 0.43
▸ P2RY2 P41231 3/20 0.43
▸ SRC P12931 2/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ DNPH1 O43598 1/20 0.43
▸ PRKAB2 O43741 1/20 0.43
▸ TRPM2 O94759 1/20 0.43
▸ LDHA P00338 1/20 0.43
▸ ADRB2 P07550 1/20 0.43
▸ FBP1 P09467 1/20 0.43
▸ ADORA1 P30542 1/20 0.43
▸ PRKAG1 P54619 1/20 0.43
▸ PRKAA2 P54646 1/20 0.43
▸ PDE4D Q08499 1/20 0.43
▸ KCNH2 Q12809 1/20 0.43
▸ PRKAA1 Q13131 1/20 0.43
▸ PDE3A Q14432 1/20 0.43
▸ TAS1R3 Q7RTX0 1/20 0.43
▸ TAS1R1 Q7RTX1 1/20 0.43
▸ P2RY11 Q96G91 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20908779 0.96 P2RY1 (0.42) P2RY1P2RY2SRCSMN1; SMN2DNPH1
SCHEMBL25691491 0.91 RNASEL (0.51) P2RY1P2RY2SRCSMN1; SMN2RNASEL
SCHEMBL24321956 0.86 FHIT (0.37) P2RY1P2RY2SRCSMN1; SMN2DNPH1
SCHEMBL22080175 0.85 NT5E (0.49) P2RY1P2RY2SRCSMN1; SMN2DNPH1
SCHEMBL24258651 0.84 RNASEL (0.45) RNASEL
SCHEMBL24258653 0.83 NT5E (0.37) P2RY1P2RY2SRCSMN1; SMN2DNPH1
SCHEMBL22080123 0.82 NT5E (0.51) P2RY1P2RY2SRCSMN1; SMN2DNPH1
SCHEMBL22080564 0.82 NT5E (0.51) P2RY1P2RY2SRCSMN1; SMN2DNPH1
SCHEMBL23679756 0.81 NT5E (0.47) P2RY1P2RY2SRCSMN1; SMN2DNPH1
SCHEMBL20908780 0.80 DTYMK (0.44) P2RY1RNASELDTYMK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11660311-B2 Cyclic dinucleotides as anticancer agents BRISTOL-MYERS SQUIBB COMPANY (US) 2023-05-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11660311-B2 Cyclic dinucleotides as anticancer agents DPYD, CD38, DUT P2RY1 776/4885P2RY2 1137/4885SRC 2328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback